David Sinclair at ARDD2022: Great release of unpublished data from David Sinclair's Lab

The Aging and Drug Discovery Conference (ARDD) 2022 is pleased to present David Sinclair from Harvard Medical School, who shares new unpublished results from his lab at Harvard Medical School.
Held in Copenhagen at the glorious Ceremonial Hall, this meeting gathers the most prominent figures of the aging and longevity research field, from scientists to clinicians, investors, developers, and everything in between. The fast growth of the conference is evidence of its great quality. In 2022 we had around 400 people on-site, and many others joined through the web.
To find out more check www.agingpharma.org #ARDD #ARDD2022 #Longevity

[@superluminal89]

From DIscord: "Obviously only a few slides, but RPE reprogramming data @ 12:55 in a mouse model of macular degeneration, and neuron reprogramming data @ 14:25.
IMO the new optomotor acuity data in mice w/ reprogrammed RPE cells look better than in their prior work in the optic nerve, but these are very different diseases/models so such a comparison isn't really appropriate, especially without data from a full paper (I'm just trying to put into context the extent of vision improvement here). Also they used an iodide model of macular degeneration - but presumably in older mice that are 12 months old, which is still quite young - which while is a standard mouse model in eye research I doubt it recapitulates normal aging and/or age-related macular degeneration well.
David also presents some early MIB-626 (his company's NMN) human trial data showing potential improvements in a few cardiovascular biomarkers like total cholesterol, non-HDL cholesterol, and also improved weight loss"